These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Nelfinavir-20200327-v3-终版.pdf (151.47 kB)

Nelfinavir Is Active Against SARS-CoV-2 in Vero E6 Cells

submitted on 27.03.2020, 12:33 and posted on 30.03.2020, 05:25 by Zhijian Xu, Hangping Yao, Jingshan Shen, Nanping Wu, Yechun Xu, Xiangyun Lu, weiliang zhu, Lan-Juan Li
Utilizing an integrative computational drug discovery approach, we predicted that nelfinavir is a potential inhibitor of SARS-CoV-2 main protease. Further docking nelfinavir to 30 potential target proteins of COVID-19, we found that nelfinavir is most probably a multi-target agent. The half-maximal effective concentration (EC50) of nelfinavir mesylate against SARS-CoV-2 was 2.89±0.65 μM while that of remdesivir was 1.00±0.34 μM, both drugs showed similar dose-response curves. Based on its high potency against SARS-CoV-2 at cellular level, its higher exposure in lung than in plasma, its good safe profile and its potential to reduce inflammation, nelfinavir deserves further exploration for the treatment of COVID-19.


Email Address of Submitting Author


Shanghai Institute of Materia Medica, Chinese Academy of Sciences



ORCID For Submitting Author


Declaration of Conflict of Interest



Logo branding